Lytix Biopharma AS's total assets for Q4 2022 were kr152.02M, a decrease of -14.30% from the previous quarter. DE:6BG total liabilities were kr16.89M for the fiscal quarter, a 25.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.